RBC Capital analyst Douglas Miehm maintained a Buy rating on Bausch Health Companies (NYSE:BHC) on Wednesday, setting a price target of $41, which is approximately 53.73% above the present share price of $26.67.
Miehm expects Bausch Health Companies to post earnings per share (EPS) of -$1.66 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Bausch Health Companies, with an average price target of $38.29.
The analysts price targets range from a high of $55 to a low of $26.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2.1 billion and a net profit of -$214 million. The company's market cap is $9.57 billion.
According to TipRanks.com, RBC Capital analyst Douglas Miehm is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 1.1% and a 42.45% success rate.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.